Fig. 3From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitusForest plot of the hazard ratios for major adverse cardiac events (MACE) and other cardiovascular (CV) endpoints [CV-related death, fatal and nonfatal (FNF) MI, FNF stroke, and all-cause mortality]Back to article page